✦ LIBER ✦

Lack of relationships between the debrisoquine (CYP2D6) and mephenytion (CYP2C19) oxidation polymorphisms and susceptibility to breast cancer

✍ Scribed by M. Jennings; H. Sweetland; C.A.D Smith; C.R. Wolf; M.S. Lennard; G.T. Tucker; H.F. Woods; K. Rogers

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Relationship between fluvoxamine pharmac

✍ O. Spigset; K. Granberg; S. Hägg; Å. Norström; R. Dahlqvist 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 155 KB

Genetic polymorphism of debrisoquine (CY

✍ S. Wanwimolruk; S. Bhawan; P. F. Coville; S. C. W. Chalcroft 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 170 KB

Polymorphism of CYP2D6, CYP2C19, CYP2C9

✍ Jónrit Halling; Maria S. Petersen; Per Damkier; Flemming Nielsen; Philippe Grand 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 290 KB

Breast Cancer Treatment Outcome With Adj

✍ Stearns, V. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Implication of Xenobiotic Metabolizing E

✍ Achraf Khedhaier; Elham Hassen; Noureddine Bouaouina; Sallouha Gabbouj; Slim Ben 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 319 KB

Genetic polymorphisms of drug-metabolizi

✍ Kostas Arvanitidis; Georgia Ragia; Maria Iordanidou; Sofia Kyriaki; Athanasia Xa 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB